Dec 04, 2019, Ardelyx lnc said about its experimental drug succeeded in regulating elevated blood phosphate levels in patients with chronic kidney disease (CKD) in a late-stage study.
As per reports, tenapanor showed a greater difference in serum phosphorus levels compared to placebo.
Approx 70% of CKD patients on dialysis continue to experience elevated phosphorus levels, also called hyperphosphatemia , at any point in time, the company said despite treatment with phosphate binders.
Iin September Ardelyx said that in another late-stage study patients treated with tenapanor and phosphate binders, the only approved therapy for hyperphosphatemia, showed a significant reduction in serum phosphorus levels compared to phosphate binders alone.
Tenapanor if approved will be the only non-binder treatment for high serum phosphorus levels in patients with chronic kidney disease on dialysis.
https://ardelyx.com/what-we-do/
